[The inhibitory effects at the α-strain of insulin-like growth factor 1 receptor on SPCA-1 and A549 lung adenocarcinoma cell lines].
BACKGROUND
Lung carcinoma is one of the most common malignant tumors in China.The increasing incidence of lung cancer has been alerted and multimodality treatments including surgery,radiotherapy,chemotherapy etc.have been highly aware.However,the outcome of treatment in lung cancer remains poor,because there is still no definite molecular targeting drug affecting its biological behavior significantly.To find an useful clinical tool,the aims of this study are to explore the effects of a novel monoclonal antibody targeting at the α-strain of insulin-like growth factor 1 receptor(IGF1-αR) on lung adenocarcinoma cell lines.


METHODS
The novel monoclonal antibody targeting at IGF1-αR was exacted by hybrid cell processes and purified by Protein G column.The effects of growth were investigated on SPCA-1 and A549 cell lines by MTT curve lines and the expression of Ki67.


RESULTS
The combination of IGF1 with IGF1-αR could be competitively inhibited by the novel monoclonal antibody significantly.Intervented by the novel monoclonal antibody,SPCA-1 and A549 cell lines proliferated more slowly than that of the respective control,with significant statistic value(P < 0.05).Besides,the expression of Ki67 showed significant downregulation under the invention of the monoclonal antibody.


CONCLUSIONS
The special monoclonal antibody extracted in our laboratory shows good affinity with IGF1-αR,and can inhibit the growth of SPCA-1 and A549 cell lines.
Fuzhou General Hospital,Fuzhou,Fujian 350025,P.R.China.
Zongyang
Z
Yu
Jian
J
Du
Xuenong
X
Ouyang
Liqing
L
Yao